FDA (CDER)
GUIDANCE DRAFT
Q3E Guideline for Extractables and Leachables
Published: 11/28/2025Detected: 3/20/2026
Summary preview
Provides draft FDA (CDER) guidance on extractables and leachables (E/L), which may shape expectations for safety and risk-based assessment of materials in drug manufacturing and packaging systems.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountmanufacturing
quality
safety
labeling
#extractables
#leachables
#packaging
#patient exposure
#risk assessment
Official Source Document Source Verified
Access the original document directly from FDA CDER.
More from FDA (CDER)
- E14 and S7B Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential--Questions and Answers (R1): Guidance for Industry10/30/2026
- Submitting Clinical Trial Data to Evaluate the Ability to Operate a Motor Vehicle10/20/2026
- Regulatory Considerations for Prescription Drug Use-Related Software10/20/2026
- Safety Reporting Requirements for INDs and BA/BE Studies: Guidance for Industry and Investigators10/19/2026
- Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products: Questions and Answers10/9/2026